Sign in

    Dave Turklin

    Managing Director and Senior Equity Research Analyst at Citizens JMP Securities

    David Turkaly is a Managing Director and Senior Equity Research Analyst at Citizens JMP Securities, specializing in the medical technology and healthcare devices sectors. He covers companies such as STERIS, Lantheus Holdings, Integra LifeSciences, Teleflex, and Stryker, with a documented success rate of 33% to 48% on his price targets and an average potential upside on recommended stocks ranging from 14% to over 50%. Turkaly has issued more than 270 ratings since joining JMP, previously holding similar research roles within the healthcare industry before Citizens' acquisition of JMP. He is a registered research analyst holding relevant FINRA securities licenses and is widely recognized for his focused expertise in medical device equity research.

    Dave Turklin's questions to STERIS (STE) leadership

    Dave Turklin's questions to STERIS (STE) leadership • Q3 2025

    Question

    Dave Turklin asked if the strong 14% order growth and high backlog in the Healthcare segment could signal a 'new normal' of mid-to-high single-digit growth for the overall business going forward.

    Answer

    SVP and CFO Michael Tokich acknowledged the strong performance and backlog in Healthcare but declined to provide forward-looking commentary on fiscal 2026 growth expectations. He reiterated that the company is very pleased with its current position but remains focused on the timing of converting the strong backlog into shipments, noting the cancellation rate remains at zero.

    Ask Fintool Equity Research AI